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The Global Person: Pig-Human Embryos,
Personhood, and Precision Medicine*
YVONNE CRIPPS**
ABSTRACT
Chimeras, in the form of pig-human embryos engineered by CRISPR-
Cas9 and other biotechnologies, have been created as potential sources of
organs for transplantation. Against that background, and in an era of
"precision medicine," this Article examines the concept of the global
genetically modified person and asks whether humanness and
personhood are being eroded, or finding new boundaries in intellectual
property and constitutional law.
INTRODUCTION
The late twentieth and early twenty-first centuries have heralded
the age of the global person-the genetically engineered human being.1
* I would like to thank James Ford of the Hu Laboratory, Indiana University, for his
extremely thoughtful comments on this article, and my research assistant, Zena Braish,
for keeping me expertly footnoted and otherwise in order. Professor Fred Aman, as the
founder and leader of the Journal for over twenty-five years, is an ever-encouraging and
inspiring colleague.
** Harry T. Ice Chair of Law, Maurer School of Law, Indiana University.
1. For recent developments, see Hong Ma et al., Correction of a Pathogenic Gene
Mutation in Human Embryos, 548 NATURE 413, 413 (2017); see also Marcia Frellick,
Research Unveiled in First Human Embryo Gene Editing in US, MEDSCAPE (Aug. 2, 2017),
http://www.medscape.com/viewarticle/883503; Review of Mitalipov Paper CRISPR'ing
Human Embryos: Transformative Work on the Edge, THE NICHE: KNOEPFLER LAB STEM
CELL BLOG (Aug. 2, 2017), https://ipscell.com/2017/08/review-mitalipov-paper-crispring-
human-embryos-transformative-work-edge/; Xiangjin Kang et al., Introducing Precise
Genetic Modifications into Human 3PN Embryos by CRISPRICas-mediated Genome
Editing, 33 J. ASSISTED REPROD. & GENETICS 581, 581 (2016); Puping Liang et
al., CRISPR/Cas9-mediated Gene Editing in Human Tripronuclear Zygotes, 6 PROTEIN &
CELL 363, 363 (2015); Ewen Callaway, Second Chinese Team Reports Gene Editing in
Human Embryos, NATURE (Apr. 8, 2016), https://www.nature.com/news/second-chinese-
team-reports-gene-editing-in-human-embryos- 1.19718.
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The global search not only for cures for illness and disease, 2 but also for
perceived enhancement, has led to a rush to eliminate, modify, and
patent certain genetic defects. In this version of globalization alchemy,
the human genome is mined globally for genetic nuggets to be shaped;
redesigned; and, in some cases, monopolized. In a recent iteration of
these trends, scientists have created pig-human embryos 3 containing
elements of both species. These embryos are designed as sources of
organs that will be recognized, or at least not rejected, by the human
immune system. The National Institutes of Health (NIH)
contemporaneously proposed an end to its ban on funding for research
that involves transplanting human stem cells into nonhuman animal
embryos. 4
The advent of such chimeras, or genetic combinations, is
complimented by the development of new gene editing technologies,
including CRISPR-Cas9, a gene editing tool that brings about what are
hoped to be precisely targeted changes to the genome of living cells. 5
CRISPR-Cas 136 and zinc finger nuclease therapy are beginning to jostle
with CRISPR-Cas9 for human gene editing primacy, with the zinc finger
therapy enabling changes to DNA in the human body. 7 Yet such
changes, when applied to reproductive cells, will alter the human gene
pool in ways that are difficult to predict.8 These changes come at a time
when individuals are attempting to do their own gene editing.9 Legal
2. Michael Nedelman, FDA Announces First US Gene Therapy Approval for Cancer
Treatment, CNN (Aug. 30, 2017, 5:07 PM), http://edition.cnn.com/2017/08/30/health/fda-
first-gene-therapy-leukemia/index.html.
3. Jun Wu et al., Interspecies Chimerism with Mammalian Pluripotent Stem Cells,
168 CELL 473, 474 (2017); Sara Reardon, Hybrid Zoo: Introducing Pig-Human Embryos
and a Rat-Mouse, NATURE (Jan. 26, 2017), https://www.nature.com/news/hybrid-pig-
human-embryos-and-a-rat-mouse-1.21378.
4. Lenny Bernstein, NIH May Allow Funding for Human-Animal Stem Cell Research,
THE WASH. POST (Aug. 5, 2016), https://www.washingtonpost.com/news/to-your-
health/wp/2016/08/05/nih-may-allow-funding-for-human-animal-stem-cell-
research/?utm term=.bd54dfOlalb4.
5. Le Cong et al., Multiplex Genome Engineering Using CRISPRICas Systems, 339
SCIENCE 819, 819 (2003).
6. David B.T. Cox et al., RNA Editing with CRISPR-Cas13, 358 SCIENCE 1019, 1019
(2017).
7. Human gene editing had previously taken place by removing cells from the human
body, editing them, and returning the edited cells to the body. James Gallagher, First
Gene-Editing in Human Body Attempt, BBC NEWS (Nov. 16, 2017), http://www.bbc
.co.uk/news/health-42009929.
8. The difficulty of predicting outcomes occurs in part because of pleiotropy, which
refers to one gene influencing numerous seemingly unrelated expressed (or phenotypic)
traits or characteristics.
9. See Alex Pearlman, Biohackers Are Using CRISPR on Their DNA and We Can't
Stop It, NEW SCIENTIST (Nov. 15, 2017), https://www.newscientist.com/article/mg23631
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questions abound, not least whether the combination of human genes
with nonhuman animal genes in organ-rich chimeras will render more
tenuous our understanding of what it is to be human. Will humanness
be redefined? Will it become increasingly difficult to decide which beings
qualify for the traditional legal protections of personhood?
I. A BRIEF HISTORY
A. Chimeras
Homer described a cross-species chimera: a fire-breathing hybrid "of
immortal make, not human, lion-fronted and snake behind, a goat in the
middle."10 The sighting of a chimera was thought to be an omen for
disaster. But it was probably the mythical centaurs of ancient Greece
that first sported a human head." Most centaurs were portrayed as
dangerously aggressive, yet, the centaur Chiron, the tutor of Asklepios,
the god of medicine, was recognized for his medical skills and wisdom. 12
Marvel, as one might, at these mythical cross-species creatures and the
vivid imaginations of their authors, modern chimeras embody not only
the promise of cures but also very real problems for present-day lawyers
and for science and society in the twenty-first century.
A chimera, in genetic parlance, is an organism or tissue that
contains at least two different sets of DNA. 13 Pig-human embryos are
chimeras: combinations of human and nonhuman animals, in embryonic
form. Such chimeras were announced in 2017, by Jun Wu; Juan Carlos
Izpisua Belmonte; and their colleagues at the Salk Institute in La Jolla,
California. 14 The chimeras were created by injecting different types of
induced pluripotent human stem cells directly into more than 1,400 pig
embryos. The resultant embryos developed post implantation in a pig
520- 100-biohackers-are-using-crispr-on-their-dna-and-we-cant-stop-it/ (last updated Nov.
16, 2017); see also DIY Bacterial Genome Engineering CRISPR Kit, AMAZON.COM,
https://www.amazon.com/DIY-Bacterial-Genome-Engineering-CRISPR/dp/BO71ZXW1TW
(last visited Mar. 1, 2018).
10. HOMER, ILIAD ch. 6, 179-82 (William F. Wyatt ed., A. T. Murray trans., Harvard
Univ. Press 2d ed. 1924).
11. The satyrs of Greek mythology, and their Roman counterparts, the fauns, had
human-like heads, but with horns. The minotaurs were essentially bulls, only their lower
half human. See WILLIAM SMITH, 1 DICTIONARY OF GREEK AND ROMAN BIOGRAPHY AND
MYTHOLOGY 666 (William Smith ed., 1849).
12. Asklepios, THEOICOM, http://www.theoi.com/Ouranios/Asklepios.html (last visited
Mar. 1, 2018).
13. Chimeric, MERRIAM WEBSTER MEDICAL DICTIONARY, http://www.merriam-
webster.com/medical/chimeric (last visited May 4, 2018).
14. Wu et al., supra note 3, at 474.
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host, a sow surrogate mother. Scientists then noted where the human
cells took hold in the developing embryos over periods of twenty-eight
days, at which point the embryos were destroyed. The different kinds of
human cells that were used were: so-called "naive" cells that resemble
cells from an earlier developmental origin with unrestricted
developmental potential; "primed" cells that have developed further, but
remain pluripotent;15 and "intermediate" cells that are somewhere in
between the other two types of cells in terms of their developmental
stage. All the human cells were modified to produce a green fluorescent
protein so that they could be identified within the newly created
chimeras. 16 The authors noted that the intermediate type of human
stem cell "contributed" most to the pig-human chimeras. 17 The team
created 186 later-stage chimeric embryos that survived up to twenty-
eight days in utero until destroyed, with an estimated about one in
one hundred thousand human cells in each embryo. 18 The aim of the
Salk team is greatly to increase the proportion of human to pig cells
with the aim of using these chimeras as sources of organs that will
not be rejected when transplanted into human beings. The greater the
proportion of human cells in the chimeras, the lesser the chance that
the human immune system will reject the organs taken from the pig-
human chimeras. These are the first documented human-nonhuman
chimeras to have survived and grown inside a nonhuman animal.
Other teams are working on alternative solutions to the shortage of
organs for transplant; experimenting, for example, with 3-D printing
of organs produced from stem cells.19 The use of nonhuman animal
organs as protein scaffoldS 20 is also showing promise.
B. Precision Medicine, CRISPR-Cas9, and a New Source of Organs
President Obama launched the Precision Medicine Initiative in
15. Pluripotent cells are immature cells or stem cells capable of giving rise to several
different cell types. What is the Difference Between Totipotent, Pluripotent, and
Multipotent?, N.Y. ST. STEM CELL SCI., https://stemcell.ny.gov/faqs/what-difference-
between-totipotent-pluripotent-and-multipotent (last visited Mar. 1, 2018).
16. Reardon, supra note 3.
17. Id.
18. Wu et al., supra note 3, at 480.
19. See Jeong Hun Park et al., Current Advances in Three-Dimensional Tissue/Organ
Printing, 13 TISSUE ENGINEERING & REGENERATIVE MED. 612, 612 (2016); see also Dina
Radenkovic et al., Personalized Development of Human Organs Using 3D Printing
Technology, 87 MED. HYPOTHESES 30, 31 (2016).
20. Clare Wilson, Donor Organs Created by Dissolving and Rebuilding Pig Livers,
NEW SCIENTIST (Oct. 30, 2017), https://www.newscientist.com/article/2151910-donor-
organs-created-by-dissolving-and-rebuilding-pig-livers/.
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2015.21 It was intended to go beyond the initial sequencing of the human
genome, with researchers collecting comparative data on numerous
individual genomes and better identifying the polymorphisms or defects
that lead to illness. The principal aim of the initiative was to find cures
or treatments for the illnesses identified as having genetic links and,
ultimately, to customize care and treatments so that they may be
tailored to individual patients or groups of patients. If successful,
precision medicine could, amongst other benefits, greatly reduce not
only the cost of such treatments but also the well-meaning yet
unnecessary suffering inflicted on patients who, because of their genetic
makeup, are unlikely actually to be helped by the existing treatments.
Positive results of this kind are already being achieved in the field of
clinical oncology, in which genetic tests can identify patients who are
not likely to benefit from existing chemotherapies used to treat breast,
prostate, and colon cancers. 22
Increasing knowledge about the role of genes that cause illness and
undesired characteristics comes at a time when the patented technology
known as CRISPR-Cas9 facilitates much more precise and targeted (if
by no means entirely predictable) modification of the human genome
than previous genetic engineering techniques. Unintended consequences
are still a feature of the technology because the genes that are edited
frequently code for more than one characteristic and not all the
interactions are known.
CRISPR-Cas9 technology uses two key molecules that introduce a
change or mutation into the DNA: first, an enzyme called Cas9 acts as a
molecular scissors by cutting the two strands of DNA at a specific
location in the genome so that pieces of DNA can then be added or
removed and, secondly, a piece of RNA called guide RNA or gRNA. This
consists of a small piece of pre-designed RNA sequence (about twenty
bases long) located within a longer RNA scaffold. The scaffold part binds
to DNA and the pre-designed sequence guides the Cas9 enzyme to the
right part of the genome so that it cuts at the intended point in the
genome. In theory, the guide RNA will bind only to the target sequence
and not to other regions of the DNA. Once the Cas9 enzyme makes a cut
across both strands of the DNA, the cell recognizes that its DNA is
21. The initiative was announced by President Obama during the 2015 State of the
Union Address. Barack Obama, President of the United States, State of the Union
Address (Jan. 20, 2015).
22. See Oncotype DX Personalizes Treatment Options and Improves Outcomes,
GENOMIC HEALTH, http://www.genomichealth.com/en-US/oncotypeiq-products/oncotype
dx.aspx (last visited Mar. 1, 2018); see also Joseph A. Sparano et al., Prospective
Validation of a 21-Gene Expression Assay in Breast Cancer, 373 NEw ENG. J. MED. 2005,
2007 (2015).
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damaged and tries to repair it. The technology can be used to introduce
changes to one or more genes in a cell. 23
CRISPR-Cas9 technology was used to assist in the creation of the
chimeras. For example, Jun Wu, of Juan Carlos Izpisua Belmonte's
team at the Salk Institute, used CRISPR technology to create mouse
embryos without the genes that cause organs to form. 24 The scientists
then injected rat stem cells into the mouse embryos and implanted the
embryos into a mouse's uterus. Because the rat cells still contained
genes for organ formation, the resulting chimeras had organs that were
composed largely of rat cells. The animals lived for up to two years, the
normal lifespan of a mouse. 25 Rat cells also grew to form a gall bladder
in a mouse, even though rats stopped developing this organ over the 18
million years since rats and mice separated evolutionarily. Jun Wu
explained that this suggests that the reason a rat does not generate a
gall bladder is not because it cannot, but because the potential has been
hidden by a rat-specific developmental program. 26
CRISPR-Cas9 has also been used to reduce the immunogenicity of
pigs by removing specific antigens. For instance, a team at Harvard led
by George Church has published a paper on using CRISPR-Cas9 to
remove endogenous retroviral genes in pigs for the purpose of reducing
immune reactions in pig-human chimeras. 27 This was no small
modification. One application of CRISPR-Cas9 operated to alter at least
sixty-two porcine retroviral genes in each pig. But these are not the only
antigenic proteins in pigs and it has been suggested that the chances of
successfully reducing immune system reactions will be improved by
23. Alex Reis et al., CRISPR/Cas9 and Targeted Genome Editing: A New Era in
Molecular Biology, NEW ENG. BIOLABS (2014), https://www.neb.com/tools-and-
resources/feature-articles/crispr-cas9-and-targeted-genome-editing-a-new-era-in-
molecular-biology; What is CRISPR-Cas9?, YOURGENOME.ORG, https://www.yourgenome.
org/facts/what-is-crispr-cas9 (last updated Dec. 19, 2016). CRISPR-Cas9 technology is
already being refined. Nicole M. Gaudelli et al., Programmable Base Editing of A* T to
G*C in Genomic DNA Without DNA Cleavage, 551 NATURE 464, 464 (2017); Cox et al.,
supra note 6, at 1024.
24. A Japanese team had created a rat/mouse chimera in 2010. That chimera was a
mouse with pancreatic tissue formed from rat cells. Toshihiro Kobayashi et al., Generation
of Rat Pancreas in Mouse by Interspecific Blastocyst Injection of Pluripotent Stem Cells,
142 CELL 787, 788 (2010).
25. Wu et al., supra note 3, at 481; Reardon, supra note 3.
26. Wu et al., supra note 3, at 475.
27. See Luhan Yang et al., Genome-Wide Inactivation of Porcine Endogenous
Retroviruses (PER Vs), 350 SCIENCE 1101, 1101, 1103 (2015); see also Dong Niu et al.,
Inactivation of Porcine Endogenous Retrovirus in Pigs Using CRISPR-Cas9, 357 SCIENCE
1303, 1303 (2017); Karen Weintraub, Gene-Editing Success Brings Pig-to-Human
Transplants Closer to Reality, SCI. Am. (Aug. 10, 2017), https://www.scientificamerican
.com/article/gene-editing-success-brings-pig-to-human-transplants-closer-to-reality/.
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combining the pig-human chimera work with CRISPE gene editing
designed to reduce antigenicity-the ability to cause the production of
antibodies. 28 This work clearly has important implications for reducing
the likelihood of the rejection of organs removed from pig-human
chimeras and transplanted into humans.
C. Global Sub-Species and Cross-Species Studies
Work in this field is being conducted across the globe with teams
from the United States, Japan, and China leading the way. But it was
not until 2001 that scientists from the United States, the United
Kingdom, Japan, France, Germany, and China, who had been working
collaboratively on what they called the Human Genome Project,
published the first analysis of the human genome sequence, 29 making
this a truly global enterprise. The following years brought further
understanding of the human genome and its polymorphisms and, in
2014, scientists comparing human, fly, and worm genomes noted that
these species have extensively shared genetics. The findings offered
cross-species insights into embryonic development and gene
regulation.30 Creations such as pig-human embryos were already
further from the realms of myth.
Also in 2014, an international team, including researchers from the
National Institutes of Health (NIH), completed the first comprehensive
characterization of genomic diversity across sub-Saharan Africa. 31 The
study provided insights into medical conditions of people of sub-Saharan
African ancestry. In 2015, an international team of scientists from the
1000 Genomes Project Consortium created the world's largest catalogue
of genomic differences among humans, 32 providing researchers with
indications of why some people are susceptible to various diseases. That
same year, transgenic zebrafish were developed as a live animal model
of mutagenesis, promising cancer researchers new methods of
28. Perspectives on Pig Human Chimera Paper, THE NICHE: KNOEPFLER LAB STEM
CELL BLOG (Jan. 26, 2017),
https://ipscell.com/2017/01/perspective-on-pig-human-chimera-paper/.
29. Eric S. Lander et al., Initial Sequencing and Analysis of the Human Genome, 409
NATURE 860, 860 (2001).
30. See Alan P. Boyle et al., Comparative Analysis of Regulatory Information and
Circuits Across Distant Species, 512 NATURE 453, 453 (2014).
31. See Deepti Gurdasani et al., The African Genome Variation Project Shapes Medical
Genetics in Africa, 517 NATURE 327, 327-32 (2015).
32. About IGSR and the 1000 Genomes Project, THE INT'L GENOME SAMPLE RESOURCE,
http://www.internationalgenome.org/about (last visited Mar. 1, 2018).
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developing pharmaceuticals. 33
Research funded by the National Human Genome Research
Institute (NHGRI), part of NIH, provided new insights into the effects
and roles of genetic variation and parental influence on gene activity in
mice and humans. 34 NIH researchers also discovered that the genomic
switches of a blood cell are crucial to regulating the human immune
system. 35 Their findings were an important step in the development of
personalized medicine for those with autoimmune disorders. The
following year, NUGRI researchers began to collaborate with physicians
and medical geneticists around the world to create the Atlas of Human
Malformation Syndromes in Diverse Populations, and NHGRI funded a
study of the impact of genomics in American Indian and Alaskan native
communities. 36
By 2016, an international team of more than 300 scientists had
conducted an extensive investigation of the underlying genetic
architecture of type 2 diabetes. 37 Their findings suggested that most of
the genetic risk for type 2 diabetes can be attributed to common shared
genomic variants. In the final paragraph of their published paper, the
team concluded that "Genome sequencing in much larger numbers of
individuals than included in the current study are [sic] needed and will
no doubt provide foundational information to guide such
experimentation and connect the results to human population variation,
physiology, and disease." 38 Connections with racial variation are being
sought. As one might imagine, these global analyses depend heavily on
information technology, not least for storage and analysis of data.
D. The Information Technology Effect
The Precision Medicine Initiative announced in 2015 was designed
to collect and compare data on large numbers of individual genomes. 39
33. See Gaurav K. Varshney et al., High-Throughput Gene Targeting and Phenotyping
in Zebrafish Using CRISPR/Cas9, 25 GENOME RES. 1030, 1030 (2015).
34. See generally James J. Crowley et al., Analyses of Allele-Specific Gene Expression in
Highly Divergent Mouse Crosses Identifies Pervasive Allelic Imbalance, 47 NATURE
GENETICS 353 (2015).
35. See Golnaz Vahedi et al., Super-Enhancers Delineate Disease-Associated
Regulatory Nodes in T Cells, 520 NATURE 558 (2015).
36. National Human Genome Research Institute (NHGRI), NAT'L INSTITUTES OF
HEALTH, https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-human-genome
- research-institute-nhgri (last updated Mar. 1, 2018).
37. Id.
38. Christian Fuchsberger et al., The Genetic Architecture of Type 2 Diabetes, 536
NATURE 41, 49 (2017).
39. Obama, supra note 21.
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The main purpose of the initiative was to find cures or treatments for
genetic illnesses. But the enterprise was inherently global, with
international genome database networks increasingly deployed for the
purposes of large-scale comparison. Several collaborations over
international databases are currently underway. Note, for example, the
International Nucleotide Sequence Database Collaboration, 40 which is a
joint effort to collect and disseminate computerized databases of DNA
and RNA sequences. It includes information from the DNA Databank of
Japan; GenBank in the United States; and the European Nucleotide
Archive, the latter based in the United Kingdom. New and updated data
on genetic nucleotide sequences contributed by research teams to each
of the three databases are synchronized by staff at each of the
collaborating organizations. 4 1
An International HapMap Consortium 42 is at work on the
International HapMap project, the aim of which is to determine the
common patterns of DNA sequence variation in the human genome and
to put this information into the public domain. 43 This international
consortium is developing a map of these patterns across the genome by
determining the genotypes of one million or more sequence variants,
their frequencies, and the degree of association between them, using
DNA samples from populations with ancestry from parts of Asia, Africa,
and Europe. It was hoped that the HapMap would allow the discovery of
sequence variants that affect common diseases and would facilitate
development of diagnostic tools and therapeutic interventions. The
Human Genome Project44 is related to the entire human genome,
including approximately 99.9 percent of the human genome that all
human beings are thought to have in common, whereas the HapMap
would characterize the common patterns within the 0.1 percent of the
genome in which we differ from each other.
In the United States, a move to digitize patients' genetic records is
40. INT'L NUCLEOTIDE SEQUENCE DATABASE COLLABORATION, http://www.insdc.org/
(last visited Mar. 1, 2018).
41. Ilene Karsch-Mizrachi et al, The International Nucleotide Sequence Database
Collaboration, 40 NUCLEIC ACIDS RES. D33, D33-D36 (2012).
42. Richard A. Gibbs et al., The International HapMap Project, 426 NATURE 789,
789 (2003).
43. The HapMap (short for "haplotype map") is a catalog of common genetic variants
known as single nucleotide polymorphisms or SNPs. Each SNP represents a difference in
a single DNA building block, called a nucleotide. These variations occur normally
throughout a person's DNA. When several SNPs cluster together on a chromosome, they
are inherited as a block known as a haplotype. The HapMap describes haplotypes,
including their locations in the genome and how common they are in different populations
throughout the world. What is the International HapMap Project?, GENETICS HOME
REFERENCE (Feb. 27, 2018), https://ghr.nlm.nih.gov/primer/genomicresearch/hapmap.
44. Gibbs et al., supra note 42, at 793.
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also much in evidence in various institutional choices. In 2015, the
Undiagnosed Diseases Network (UDN) opened the UDN Gateway, an
online patient application, to streamline the patient application process
across its individual clinical sites. The same year, the Electronic
Medical Records and Genomics Network (eMERGE) began its Phase III
with nine new investigator sites, two central sequencing and genotyping
facilities, and a coordinating center.45 In 2016, NHGRI funded
researchers at its Centers of Excellence in Ethical, Legal and Social
Implications Research program to examine the use of genomic
information in the prevention and treatment of infectious diseases;
genomic information privacy; and communication about prenatal and
newborn genomic testing results.46
That year, NHGRI also launched the Centers for Common Disease
Genomics, which uses genome sequencing to explore the genomic
aspects of common maladies such as heart disease, diabetes, stroke, and
autism. Concurrently, NHGRI awarded approximately 11.1 million
dollars to support research aimed at identifying differences-called
genetic variants-in the less-studied regions of the genome that are
responsible for regulating gene activity.47 The Genomic Healthcare
Branch of the NIH convened a meeting with fourteen family health
history tool developers and vendors to assess their approaches to
addressing gaps in current electronic health records. 48
Others have addressed concerns about the privacy of genetic data
and the potentially adverse uses of this information, 49 but it is
important to record here recent threats to the anonymity of stored
genetic data. The Genetic Information Nondiscrimination Act of 200850
and the Americans with Disabilities Act of 199051 are amongst the laws
that guard the privacy of genetic information and protect it from
adverse uses by employers and insurers. But a recent, little noted, bill,
associated with proposed revisions of the Patient Protection and
45. National Human Genome Research Institute (NHGRI), supra note 36.
46. Id.
47. Id.
48. Id.
49. See, for example, Janet A. Kobrin, Comment, Medical Privacy Issue:
Confidentiality of Genetic Information, 30 UCLA L. REV. 1283 (1983) (discussing how the
law and courts have not kept pace with the widespread and increasing public use of
genetic counseling services); George J. Annas, Privacy Rules for DNA Databanks:
Protecting Coded Future Diaries', 270 JAMA 2346, 2346 (1993) ("Current rules for
protecting the privacy of medical information cannot protect either genetic information or
identifiable DNA samples stored in databanks.").
50. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat.
881 (2008) (codified as amended in scattered sections of 29 U.S.C. and 42 U.S.C.).
51. 42 U.S.C. § 12101 (1990) (amended 2009).
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Affordable Care Act, 52 whilst purporting to support the Affordable Care
Act's incentivization of wellness, could have removed privacy protections
from those seeking to enjoy the benefit of the wellness incentives. The
Preserving Employee Wellness Programs Bill of 2017 is worth quoting
in full and would have exempted
workplace wellness programs from: (1) limitations under
the Americans with Disabilities Act of 1990 on medical
examinations and inquiries of employees, (2) the
prohibition on collecting genetic information in
connection with issuing health insurance, and (3)
limitations under the Genetic Information
Nondiscrimination Act of 2008 on collecting the genetic
information of employees or family members of
employees. This exemption applies to workplace
wellness programs that comply with limits on rewards
for employees participating in the program. Workplace
wellness programs may provide for more favorable
treatment of individuals with adverse health factors,
such as a disability. Collection of information about a
disease or disorder of a family member as part of a
workplace wellness program is not an unlawful
acquisition of genetic information about another family
member.53
If passed into law, this bill would, under the shading umbrella of other
proposed changes to healthcare law, have undermined the genetic
privacy protections established in the Genetic Information
Nondiscrimination Act and the Americans with Disabilities Act. And
that at a time when our expanded understanding of genetics makes it
increasingly easy to identify supposedly anonymous individuals from
databases containing their genetic information.
E. Ethical Concerns
This article includes consideration of human gene-editing and the
creation of pig-human embryos as sources of organs and spare parts.
Those with a sense of history, as well as of science and law, will
appreciate that the medical and legal histories of the science of genetics
have not been uniformly glorious. Sir Francis Galton, a half-cousin of
52. Pub. L. No. 111-148, 124 Stat. 119 (2010).
53. H.R. 1313, 115th Cong. (2017).
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Charles Darwin, invented the term eugenics in 188354 to describe a set
of ideas discussed at least since Plato recommended selective breeding
to create a "guardian" class. 5 5
Galton's form of eugenics through controlled breeding was popular
amongst still celebrated English and Irish figures, including George
Bernard Shaw, Bertrand Russell, Sidney and Beatrice Webb, and John
Maynard Keynes; it was also enthusiastically espoused by Hitler in
Mein Kampf,56 along with sterilization legislation already implemented
at that time in numerous U.S. states. The legislation, which was copied
by Nazi Germany,57 legalized enforced sterilization of various persons
deemed to be defective-a position upheld as constitutional in the
United States by Justice Oliver Wendell Holmes, writing the decision of
the U.S. Supreme Court in Buck v. Bell in 1927.58 The practice of forced
sterilization continued in certain instances in the United States until
the 1980s, and attenuated forms of it arguably still exist within the
criminal justice system of today. 5
Against that background, it is significant that those working in the
field of genetic engineering have been the first to identify ethical
questions about their own experiments. Dr. Jun Wu, in announcing the
pig-human embryos, raised issues about the percentage of human to
nonhuman cells in the chimeras. 60 The following was written by
Professor Paul Knoepfler, shortly before the pig-human embryos were
announced by the team at Salk, and other chimeras were announced by
some of Knoepfler's own colleagues at UC Davis:
As a stem cell and developmental biologist, I find the
54. See FRANCIS GALTON, INQUIRIES INTO HUMAN FACULTY AND ITS DEVELOPMENT (JM
Dent & Sons 2d ed. 1907) (1883) (describing how eugenics refers to the science of
improving stock including human races or strains of blood); Eugenics, STAN.
ENCYCLOPEDIA OF PHIL. (July 2, 2014), https://plato.stanford.edu/entries/eugenics/.
55. See Book 1 of Plato's Socratic dialogue in PLATO, The Republic of Plato, in 2 THE
WORKS OF PLATO: A NEW AND LITERAL VERSION, CHIEFLY FROM THE TEXT OF STALLBAUM 1
(Henry Davis trans., London, George Bell & Sons 1879) (describing how the different
classes in Athenian society were determined by eugenics).
56. ADOLF HITLER, MEIN KAMPF (Stackpole Sons trans., 1939) (1925).
57. STEFAN KUHL, THE NAZI CONNECTION: EUGENICS, AMERICAN RACISM, AND GERMAN
NATIONAL SOCIALISM 86 (2002).
58. See 274 U.S. 200 (1927).
59. See Sam P.K. Collins, Tennessee Prosecutor Insisted Woman Undergo Sterilization
as Part of Plea Deal, THINKPROGRESS (Mar. 30, 2015, 4:41 PM),
https://thinkprogress.org/tennessee-prosecutor-insisted-woman-undergo-sterilization-as-
part-of-plea-deal-alad95a5e045/; see also 4 Cases of Sterilization as Part of Plea Deal,
USA TODAY (Mar. 28, 2015, 2:42 PM), https://www.usatoday.com/story/news/nation
/2015/03/28/cases-where-sterilization-was-part-of-plea-negotiations/70593962/.
60. See Wu et al., supra note 3, at 479-80.
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prospect of chimera research exciting, and generally
support this work, as long as it is conducted under
appropriate oversight and training. But there are tough
bioethical questions here, too.
For instance, how long should human chimeras be
permitted to develop in a research laboratory? There is
no universal, concrete answer, but this question must be
discussed and clear guidelines established depending on
the number of human cells used.
How do we handle human cells being present in a
developing chimeric brain? How many human cells
would be too many, risking creating a brain that has
substantial human attributes? There is a Catch-22
situation here. The closer you get to the valuable range
for neuroscience research (at least a few percent human
neurons, for instance, in the chimeric brain), the
thornier the ethics get.
To illustrate the complexity, we can look at the example
of a recent study 61 in which scientists created chimeric
mice with a type of human brain cell called glia; these
cells were present in a high abundance in the mouse
brains. While glia are not believed to directly contribute
to human thought, as neurons do, these chimeric mice
were much smarter than normal mice. For instance, the
chimeras were about twice as good at navigating mazes
as regular mice and exhibited other signs of exceptional
memory. This intriguing finding also points to the
complexities of possible human chimera outcomes.
There's no clear dividing line on the question of "overly"
human chimeric brains because we lack an
understanding of at what point "humanization" of an
animal brain could lead to more human-like thought or
consciousness. We don't even know when this happens
in the normal developing human brain.
What if a research team, only after studying a chimeric
61. See Chen Chen et al., Humanized Neuronal Chimeric Mouse Brain Generated by
Neonatally Engrafted Human iPSC-derived Primitive Neural Progenitor Cells, JCI
INSIGHT, Nov. 17, 2016, at 1.
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brain, realized that despite careful planning they had
created a chimera that had an unexpectedly high
number-say, 50 percent-of human neurons? Is it then
retroactively unethical to have made and used that
chimera in research? Did that chimera potentially fall
into some uncomfortable gray zone between an animal
and human research subject? What if researchers
developed an organ transplant chimera that was all pig
except for one human kidney, but it also accidentally
had human sperm or eggs? Is that ethically okay, as long
as it isn't allowed to breed?
Other tough questions are popping up as well in related
areas of cutting-edge research using human pluripotent
stem cells. For example, researchers are now able to
grow miniature versions of human brains and other
organs from pluripotent stem cells in a dish in the lab.
This powerful research on so-called human "organoids"
has tremendous potential for biological research and
organ transplants. But along with that potential come
profoundly challenging questions. What if human mini-
brains in a dish could "think" or be conscious at a certain
level? Some scientists believe that could never happen. I
am not so sure that "never" is a safe response. These are
not just philosophical musings. While my own laboratory
does not do chimera research, right now there are
human mini-brains in development. 62
In a more recent article, written after the announcement of the pig-
human embryos, Professor Knoepfler stated:
Even with complementation (where for example a pig
chimera would ideally only have human cells
contributing to one organ such as a kidney or pancreas)
one of the ethical dilemmas is that the chimeras would
have to be taken to term in order to get a usable human
pancreas. It is unclear if taking a human-animal
62. Paul Knoepfler, Human Chimera Research's Huge (and Thorny) Potential, WIRED
(Sept. 19, 2016, 7:00 AM), https://www.wired.com/2016/09/human-chimera-researchs-
huge-thorny-potential/.
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chimera to term could be ethically permissible. In [the]
paper, 63 the team isolated the human-pig chimeras for
analysis very early in development. Other ethical
challenges include avoiding excessive (however one
defines that) human cell contribution to chimeric brains
and any human contribution to germ [or reproductive]
cells. Potential safeguards for the latter include never
letting the animals be bred or always including a genetic
change making them sterile or both. Overall, this is
exciting research in an ethically challenging arena. The
real hope here long term for a new source of organs for
transplants is extremely important given the massive
need amongst patients, many of whom die on the
waiting list. This development also makes starting to
tackle the bioethical issues now rather than later a wise
choice. 64
These are clearly extremely important questions for lawyers, scientists,
ethicists, and society in general; yet, thus far, lawyers and lawmakers
have tended to engage with genetic engineering mainly in the relatively
narrow arena of patent law.
II. THE GENE RUSH: PATENT CLAIMS AND A CHRONICLE OF PERCENTAGES
FORETOLD
In 1997, the cell biologist Stuart Newman foreshadowed 2017's pig-
human embryos when he applied to the U.S. Patent and Trademark
Office (USPTO) for a patent on proposed "chimeric embryos and animals
containing human cells." 65 The embryos were created for the purpose of
providing organs for transplant into humans, which is also the main
purpose of the pig-human embryo work. The patent application was
ultimately rejected in 2005.66 The USPTO offered some remarks in an
early press release, stating that a human-nonhuman chimera may be
ineligible for patent protection because of a failure to meet the moral
63. See Wu et al., supra note 3, at 484.
64. Perspectives on Pig Human Chimera Paper, supra note 28.
65. Chimeric Embryos and Animals Containing Human Cells, U.S. Patent Application
No. 08/993,564 (filed Dec. 18, 1997) (status abandoned for failure to respond to office
action).
66. See Rick Weiss, U.S. Denies Patent for a Too-Human Hybrid, WASH. POST, Feb. 13,
2005, at A03.
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utility requirement under § 101,67 and in a later decision letter to
Newman, rejecting the application because human beings are not
patentable subject matter. 68 Yet this left considerable doubt as to how it
might be determined whether the subject of such a patent application
was too human to qualify for a patent, as the USPTO had decided in
this instance.
As far back as 1987, after the decisions in Diamond v.
Chakrabarty69 and Ex Parte Allen,70 the USPTO announced with
express, but unspecific, reference to the Constitution,71 a policy that
human beings would not be considered patentable subject matter. 72 The
policy was later included in Section 2105 of the Manual of Patent
Examining Procedure, which states that if "the broadest reasonable
interpretation of the claimed invention as a whole encompasses a
human being, then a rejection under 35 U.S.C. 101 must be made
indicating that the claimed invention is directed to non-statutory
subject matter." 73
Yet it was not until 2011 that Congress passed Section 33(a) of the
America Invents Act, 74 which provides that: "Notwithstanding any other
67. See Press Release, U.S. Patent & Trademark Office, Facts on Patenting Life Forms
Having a Relationship to Humans (Apr. 1, 1998), https://www.uspto.gov/about-us/news-
updates/facts-patenting-life-forms-having-relationship-humans.
68. See Patent Application is Disallowed as 'Embracing' Human Being, 58 Pat.
Trademark & Copyright J. (BNA) No. 1430, at 203 (June 17, 1999); see also Yvonne
Cripps, The Art and Science of Genetic Modification: Re-Engineering Patent Law and
Constitutional Orthodoxies, 11 IND. J. GLOBAL LEGAL STUD. 1, 21 (2004); Weiss, supra note
66.
69. In Chakrabarty, the Supreme Court held that a genetically engineered
pseudomonas bacterium, modified to consume crude oil, was patentable because the
inventor had "produced a new bacterium with markedly different characteristics from any
found in nature, and one having the potential for significant utility. His discovery is not
nature's handiwork, but his own ..... 447 U.S. 303, 310 (1980); see also Cripps, supra
note 68, at 8.
70. See Ex parte Allen, 2 U.S.P.Q.2d (BNA) 1425, 1426 (B.P.A.I. Apr. 3, 1987)
(involving a patent on polyploid oysters).
71. For further analysis of constitutional aspects, see my discussion of humanness,
personhood, and dignity, infra page 721.
72. Donald J. Quigg, Animals-Patentability, 1077 OFF. GAZ. PAT. & TRADEMARK
OFFICE 24 (1987). This policy statement was unsuccessfully challenged in Animal Legal
Def. Fund v. Quigg, 932 F.2d 920 (1991), in which it was held that judicial review is rare
in such cases because third party plaintiffs, under the Administrative Procedures Act, lack
standing to challenge the Patent and Trademark Office's interpretation of existing law.
73. U.S. PATENT & TRADEMARK OFFICE, U.S. DEP'T OF COMMERCE, MPEP § 2105 (8th
ed. Rev. 9, Aug. 2012).
74. Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284, 340 (2011)
(codified as amended in scattered sections of 35 U.S.C.). Research by Gleicher and Tang
which "involved the mixing of embryonic cells of different genders," see Norbert Gleicher
& Ya Xu Tang, Blastomere Transplantation in Human Embryos May Be a Treatment for
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provision of law, no patent may issue on a claim directed to or
encompassing a human organism."7 5 Picture and pity those in the
USPTO, who, having awaited legislative guidance for decades, were still
left without an accompanying statutory definition or guidance on what
constitutes a "human organism" for the purposes of the legislation. The
words "directed to or encompassing" are bound to lead to trouble in their
own right, but trouble perhaps of a more manageable kind than the still
undefined "human organism." Will the presence of more than 50 percent
human genes, or some other arbitrary percentage, become a criterion or
even the determinant for denial of patents on human-nonhuman animal
chimeras?
In general, and especially after the Roslin case, 76 it might be
thought that human organisms are not novel for the purposes of patent
law under 35 U.S.C. § 102. But the Roslin case involved the defeat of a
patent on a cloned creature ("Dolly," the sheep clone), not a deliberately
genetically engineered chimera. A human or nonhuman animal
modified to be a chimera could be regarded as highly novel and a
product of man rather than nature for the purposes of patent law. Even
the decision in Roslin might be questioned on the ground that no
mammal, such as Dolly, had ever been invented by somatic cell nuclear
transfer (as opposed to embryo splitting).77 That nuclear transfer into a
donor egg cell left Dolly with mitochondrial DNA from the egg cell
donor, in addition to the DNA from the somatic cell donor. It is also
important to note that even clones are not epi-genetically7 8 identical to
Single Gene Diseases, 81 FERTILITY & STERILITY 977, 980-81 (2004), spurred Congress to
introduce the Weldon Amendment, first proposed as a rider to the Commerce-Justice-
State Appropriations bill for fiscal year 2004, see H.R. 2799, 108th Cong. § 801 (2003), and
passed as part of the Consolidated Appropriations Act of 2004. It stated that "[n]one of the
funds appropriated or otherwise made available under this Act may be used to issue
patents on claims directed to or encompassing a human organism." H.R. 2799, supra.
Congress reenacted the amendment each year until it was implemented as section 33(a) of
the America Invents Act. See Ava Caffarini, Directed to or Encompassing a Human
Organism: How Section 33 of the America Invents Act May Threaten the Future of
Biotechnology, 12 J. MARSHALL REV. INTELL. PROP. L. 768, 776-77 (2013); see also Yaniv
Heled, On Patenting Human Organisms or How the Abortion Wars Feed into the
Ownership Fallacy, 36 CARDOZO L. REV. 241 (2014) (discussing the effects of section 33 of
the America Invents Act).
75. H.R. 2799, supra note 74.
76. See In Re Roslin Inst. (Edinburgh), 750 F.3d 1333 (Fed. Cir. 2014) (cloned
mammals are not patentable subject matter). See also Ass'n for Molecular Pathology v.
Myriad Genetics, Inc., 569 U.S. 576 (2013), in which the Supreme Court ruled that merely
isolated human DNA is an unpatentable product of nature.
77. Cripps, supra note 68, at 9-10.
78. The word "epigenetic" translates from the Greek word "epi" to mean upon the
genetic sequence. The term has come to refer to any process, including environmental
influence, that alters gene activity or expression (the phenotype) (for example, by
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the creatures from which they are cloned. So, even Dolly, though a
clone, was arguably novel and markedly different from other sheep. But
how marked must the marked in "markedly different" be? The court in
Roslin decided this issue, in part, on the more narrowly technical point
that such differences from other sheep as are identified here were not
expressly stated in the claims in the Roslin Institute's patent
application. As indicated above, however, a deliberately genetically
modified creature, especially a chimera, is less likely than a clone to be
barred from patentability by being viewed as a product of nature, as
opposed to a product of man.
To be patented, an invention must, in broad terms, be novel,
nonobvious, and useful. This latter requirement is known in patent law
as utility. In Lowell v. Lewis, Justice Story identified a further
requirement of what has come to be known as moral utility. He stated:
All that the law requires is, that the invention should
not be frivolous or injurious to the well-being, good
policy, or sound morals of society. The word 'useful,'
therefore, is incorporated into the [patent] act in
contradistinction to mischievous or immoral. For
instance, a new invention to poison people, or to promote
debauchery, or to facilitate private assassination, is not
a patentable invention. 7
Using this moral utility doctrine, which is not enshrined in statute
as it is in Europe, the U.S. courts invalidated patents on inventions,
such as gaming machines, well into the twentieth century.8 0 In the
Juicy Whip case,81 the Court of Appeals for the Federal Circuit cast
doubt on the doctrine and it began to fall into disuse, though it found its
way into the twenty-first century in Geneva Pharmaceuticals, Inc. v.
Glaxosmithkline PLC., in which the court noted that a "patent possesses
utility 'if it will operate to perform the functions and secure the results
intended, and its use is not contrary to law, moral principles, or public
switching genes on and off) without changing the underlying DNA sequence (the
genotype), and leads to modifications that can be transmitted to daughter cells (although
experiments show that some epigenetic changes can be reversed). See Bob Weinhold,
Epigenetics: The Science of Change, ENVTL. HEALTH PERSP., Mar. 2006, at A160, A163.
79. Lowell v. Lewis, 15 F. Cas. 1018, 1019 (C.C.D. Mass. 1817).
80. Benjamin D. Enerson, Note, Protecting Society from Patently Offensive Inventions:
The Risk of Reviving the Moral Utility Doctrine, 89 CORNELL L. REV. 685, 686-88 (2004);
Robert P. Merges, Intellectual Property in Higher Life Forms: The Patent System and
Controversial Technologies, 47 MD. L. REV. 1051, 1063 (1988).
81. Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364, 1366-68 (Fed. Cir. 1999).
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policy."' 82 And it is, of course, also open to the Supreme Court to
revitalize and deploy the moral utility doctrine.
For all the infelicities of the moral utility doctrine, which turns
patent examiners and appellate bodies into understandably reluctant
arbiters of morality with little or no legislative guidance, a patent on a
significantly human chimera may provide the impetus for the Supreme
Court to revive the doctrine in the absence of a legislative definition of a
"human organism" for the purposes of section 33(a) of the America
Invents Act.
Because patents are territorial in the sense that they only protect
the inventor in the country, block, or jurisdiction in which a patent is
granted, American and other inventors may well wish to patent their
inventions in other jurisdictions, including Europe, under, inter alia, the
European Patent Convention (EPC). Article 53(a) of the EPC expressly
prohibits the granting of patents which would be "contrary to ordre
public or morality." 83 The same prohibition appears in Article 6 of the
European Directive on the Legal Protection of Biological Inventions, 84
which states that, in the context of European patent law:
1. Inventions shall be considered unpatentable where
their commercial exploitation would be contrary to ordre
public or morality; however, exploitation shall not be
deemed to be so contrary merely because it is prohibited
by law or regulation.
2. On the basis of paragraph 1, the following, in
particular, shall be considered unpatentable:
(a) processes for cloning human beings;
82. Geneva Pharms., Inc. v. Glaxosmithkline PLC, 213 F. Supp. 2d 597, 610 (E.D. Va.
2002) (citing Callison v. Dean Novelty Co., 70 F.2d 55, 58 (10th Cir. 1934)) (emphasis
added).
83. Convention on the Grant of European Patents, art. 53(a), Oct. 5, 1973, 1065
U.N.T.S. 255 [hereinafter Patent Convention]. Note also that, under Article 27(2) of the
TRIPS agreement, "Members may exclude from patentability inventions, the prevention
within their territory of the commercial exploitation of which is necessary to protect 'ordre
public' or morality, including to protect human, animal or plant life or health or to avoid
serious prejudice to the environment, provided that such exclusion is not made merely
because the exploitation is prohibited by their law." The Agreement on Trade-Related
Aspects of Intellectual Property Rights, Annex 1C, art. 27(2), Apr. 15, 1994, 1869 U.N.T.S
299.
84. Council Directive 98/44, art. 6, 1998 O.J. (L 213) 13, 18-19 (EC),
http://data.europa.eu/eli/dir/1998/44/oj [hereinafter Biotech Directive].
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(b) processes for modifying the germ line genetic
identity of human beings;
(c) uses of human embryos for industrial or
commercial purposes;
(d) processes for modifying the genetic identity of
animals which are likely to cause them suffering
without any substantial medical benefit to man or
animal, and also animals resulting from such
processes.85
Philip Grubb has addressed the distinction between ordre public
and morality, stating that adultery in private may be considered
immoral, but, if performed in the public street, might be viewed as
contrary to ordre public.86 He also argues that a breach of ordre public
means more than what English law would regard as a disturbance of
the peace; suggesting that, under German law, it would mean a
violation of a basic constitutional right, such as the right to life,
personal freedom, human dignity, and freedom from bodily harm.8 7 His
analysis also serves to illustrate the problem of different standards of
morality in different jurisdictions. Article 6 (2) of the European
Directive is focused on processes and uses, rather than the products of
processes, and thus none of the unpatentable inventions listed in Article
6 (2) appears squarely to cover the pig-human embryos, which is not of
course to say that they may not be regarded as immoral in terms of
Article 6 (1). In practice, however, although the morality of an invention
85. Id. Note also that the EPO has revised European patent regulations to exclude
from patentability plants and animals resulting from essentially biological breeding
practices. The EU Directive had contained a much debated ambiguity, which excluded
biological breeding processes themselves from patentability, but did not clearly prevent
the patenting of the plants and animals resulting from those processes. The European
Commission released a notice in November 2016 asserting that it was the European
Parliament's intention that not only such breeding processes, but also their resulting
offspring, are unpatentable. See Commission Notice on Certain Articles of Directive 98/44,
2016 O.J. (C 411) 3. The EPO has now amended the regulations and the new rules took
effect on 1 July 2017. Patent Convention, supra note 83, at 419-20 (as amended by
Decision of the Admin. Council of 29 June 2017 amending Rules 27 and 28 of the
Implementing Regulations to the European Patent Convention Decision (CA/D 6/17), A56
(June 29, 2017)); see also Steven J. Zweig, Selected Developments in Biotechnology Law
and the Biotechnology Industry, 36 BIOTECHNOLOGY L. REP. 147, 147 (2017).
86. See PHILIP W. GRUBB ET AL., PATENTS FOR CHEMICALS, PHARMACEUTICALS, AND
BIOTECHNOLOGY: FUNDAMENTALS OF GLOBAL LAW, PRACTICE, AND STRATEGY 343 (6th ed.
2016).
87. Id.
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is to be taken into account in European patent law, patent examiners
and appellate bodies have been very reluctant to decide that any
particular invention is immoral or contrary to public order, either under
Article 53(a) of the EPCS8 or Article 6 of the European Directive, though
abhorrence or unacceptability to members of the public have sometimes
been referred to as the determining factors or tests.8 9 Are the pig-human
embryos, especially if brought to term, abhorrent or unacceptable?
III. HUMANNESS, PERSONHOOD, AND DIGNITY
The following definition of the words "person" and "human being"
appears in 1 U.S.C. § 8(a): "In determining the meaning of any Act of
Congress, or of any ruling, regulation, or interpretation of the various
administrative bureaus and agencies of the United States, the words
'person', 'human being', 'child', and 'individual', shall include every
infant member of the species homo sapiens who is born alive at any
stage of development."9 0 While the words "at any stage of development"
are interesting in this context, (not least in terms of the stem cells at
various stages of development that are used to create chimeras), 91 the
definition casts little light on chimeras involving human genes-such
creatures having been quietly moored in the realms of myth at the time
the section was drafted. The reference to the species homo sapiens
might at first sight be thought to be helpful in our inquiry. But, as homo
sapiens is the only extant human species, we are drawn back to the
question of how we decide whether or when a chimera substantially
involving human genes, mixed with nonhuman animal genes, would
qualify-or fail to qualify-as a member of that species. We are, after
all, in scientific terms, the human animal: members of the animal
kingdom.
The Thirteenth Amendment to the U.S. Constitution arguably
88. See the patent granted on the "Harvard mouse." European Patent No. EP0169672
(application published Jan. 29, 1986); Decisions of the Examining and Opposition
Divisions, OFFICIAL J. EUROPEAN PAT. OFF., Oct. 1992, at 556, 588. Though contrast with
that the decision taken by the European Patent Office on the same day on the Upjohn
mouse. Bioethics and Patent Law: The Case of the Oncomouse, WIPO MAGAZINE (June
2006), http://www.wipo.int/wipo-magazine/en/2006/03/article_0006.html. See also the
decision of the Canadian Supreme Court in Harvard Coll. v. Canada (Comm'r of Patents),
[2002] 4 S.C.R. 45 (Can.).
89. See, for example, R. v. Leland Stanford/Modified Animal, 2002 Eur. Pat. Off. Rep.
2, 16, 23 (Opposition Div.) (applying the public abhorrence test).
90. 1 U.S.C. § 8(a) (2018). Fetuses are not constitutional persons under the Fourteenth
Amendment. Roe v. Wade, 410 U.S. 113 (1973).
91. See 1 U.S.C. § 8(a) (2018).
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prohibits patents on human beings, 92 and, interestingly, unlike, for
example, the Fifth and Fourteenth Amendments, confers protections on
a "party" rather than a person.93 It binds private citizens, unlike other
constitutional provisions which apply only to state actors. The
Fourteenth Amendment to the Constitution confers privacy rights and
personhood on persons, as defined in constitutional law. 94
I have written elsewhere about the possible application of the
Thirteenth and Fourteenth Amendments to the protection of human
clones.95 At least in the case of a clone of a non-genetically-modified
human being, there should be little doubt that the clone is human and
thus entitled to the protections of the Constitution. But how much
nonhuman DNA must be incorporated in a chimera before it loses
constitutional protections? Or, the obverse, how much human DNA
must be embodied in a nonhuman animal before it gains those
protections? There will be dispute about how we define human DNA.
How do we decide which entities are persons? We know that
corporations and certain other collective entities qualify.96 The
distinction between human and other persons for constitutional
purposes is sometimes discussed in terms of a distinction between so-
called natural persons and legal or juridical persons.9 7 But it is unlikely
that creatures such as pig-human chimeras would not be regarded as
persons solely on the grounds that they are not truly natural, as
opposed to man-made or modified by man. "Natural" in this
jurisprudential usage seems to refer more to the biological or animate,
as opposed to the inanimate in the case of a corporation, though it can
be argued that a corporation is simply an aggregation or collective of
individual living persons (universitas personarum) and gains its status
as a person in that way.98
Section 1, Article 2, of the Constitution sets forth the eligibility
requirements for serving as President of the United States as follows:
"No Person except a natural born Citizen, or a Citizen of the United
States, at the time of the Adoption of this Constitution, shall be eligible
92. Cripps, supra note 68, at 18-20.
93. George Rutherglen, State Action and the Thirteenth Amendment, 94 VA. L. REV.
1367 (2008).
94. See, e.g., Roe, 410 U.S. at 113.
95. Cripps, supra note 68, at 18-20.
96. Santa Clara Cty. v. S. Pac. R.R., 118 U.S. 394, 396 (1886) (equal protection);
Chicago, Milwaukee & St. Paul Ry. Co. v. Minnesota, 134 U.S. 418, 456-457 (1890) (due
process).
97. Louisville, Cincinnati & Charleston R.R. v. Letson, 43 U.S. 497, 519-21 (1844).
98. Pembina Consol. Silver Mining & Milling Co. v. Pennsylvania, 125 U.S. 181, 189
(1888).
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to the Office of President . . . ."9 The phrase "natural-born Citizen" is
not used in the Fourteenth Amendment, though the latter does extend
its protections to "all persons born or naturalized in the United
States."100 Chimeras may be born in relatively conventional ways so the
word "born" does not rule out chimeras. But what does "natural" mean
in this context? It seems mainly to qualify the word "born" and perhaps
distinguish the "natural born" from those who are naturalized.
As we have already seen, there is a distinction between
constitutional personhood and humanness. Self-awareness does not
seem to be the key to either humanness or constitutional personhood,
especially for corporations as persons, though that depends somewhat
on how one defines awareness and on whose part it should exist in a
corporation. Self-awareness is certainly not necessary for personhood,
especially at the individual level. At the species level, it might be
observed that members of the species Homo sapiens are generally
characterized by self-awareness even if individual persons, for example,
those on a ventilator, might no longer have self-awareness; though the
legal system might deem such individuals not to be live persons if there
has been total (including brain stem) brain death. 101 We also still treat
anencephalic babies, born with little or no functioning cerebrum, as both
human and entitled to the protections of constitutional personhood,
though the American Medical Association briefly dissented from that
view in the past, in a bid to use severely anencephalic babies as a source
for much-needed organs. 102
Do international instruments provide more answers than domestic
law to questions of whether human-nonhuman chimeras qualify for
personhood or even designation as human? In the international arena,
attempts have been made to protect "dignity," presumably from
abhorrent or unacceptable assaults,10 3 but, again, the prerequisite for
the international treaty protections of dignity is that those whose
dignity is being protected are defined as human. The Oviedo Convention
for the Protection of Human Rights and Dignity of the Human Being
with Regard to the Application of Biology and Medicine: Convention on
Human Rights and Biomedicine 104 might be thought to throw some light
99. U.S. CONST. art II, § 1.
100. U.S. CONST. amend. XIV.
101. See UNIF. DETERMINATION OF DEATH ACT § 1 (NAT'L CONFERENCE OF COMM'RS ON
UNIF. STATE LAWS 1980).
102. See BARRY R. FURROW ET AL., HEALTH LAW: CASES, MATERIALS AND PROBLEMS
1271-88, 1509-34 (7th ed. 2013).
103. See Cripps, supra note 68, for a discussion of those words in the context of patent
law.
104. Convention for the Protection of Human Rights and Dignity of the Human Being
with regard to the Application of Biology and Medicine: Convention on Human Rights and
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on this issue, though the United States is not a signatory. The Oviedo
Convention contains provisions that relate to concerns about research
into the human genome. It addresses genetic testing, the storage of
genetic data and modification of the human genome. Genetic testing as
a tool for discrimination is prohibited under Article 11, while Article 12
allows genetic testing only to improve health or for scientific research
linked to health purposes. Similarly, Article 13 generally prohibits
modification of the human genome, unless for health-related purposes.
Because the Convention was signed as far back as 1997, one can
perhaps forgive drafters and signatories for failing to foresee that a
definition of "human" might well be required. Some might argue that a
chimera, such as a pig-human, is not a human for the purposes of the
protections offered by the Convention, depending on how much
nonhuman DNA the chimera contains. There might, for example, not be
discrimination against a human if the being discriminated against is
deemed not to be sufficiently human. These questions should not be
regarded as merely theoretical, as we have noted above in regard to the
already expressed concerns of cell biologists working in institutions
where embryonic human-nonhuman chimeras have been created. 105 Nor
is the Oviedo Convention alone in failing to define human beings or
persons for the purposes of the proffered international legal protection.
The same problem is, for example, evident in UNESCO's Universal
Declaration on the Human Genome and Human Rights; 106 UNESCO's
International Declaration on Human Genetic Data; 107 UNESCO's
Universal Declaration on Bioethics and Human Rights; 108 and the UN's
International Covenant on Economic, Social and Cultural Rights. 109
CONCLUSION
Socrates's defense of the importance of the examined life110 can be
Biomedicine, opened for signature Apr. 4, 1997, 2137 U.N.T.S. 171 [hereinafter
Convention on Human Rights] (entered into force Jan. 12, 1999).
105. See Wu et al., supra note 3, at 479-80 as discussed on pages 712-715 of this
article.
106. UNESCO Res. 29 C/16, Universal Declaration on the Human Genome and Human
Rights (Nov. 11, 1997).
107. UNESCO Res. 32 C/22, International Declaration on Human Genetic Data (Oct.
16, 2003).
108. UNESCO Res. 33 C/36, Universal Declaration on Bioethics and Human Rights
(Oct. 19, 2005).
109. International Covenant on Economic, Social and Cultural Rights, Dec. 16, 1966,
993 U.N.T.S. 3.
110. At his trial, see THOMAS C. BRICKHOUSE & NICHOLAS D. SMITH, PLATO'S SOCRATES
201 (1994). And in Book II of his Socratic dialogue, Republic, Plato imagines Socrates
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seen to have additional layers of significance in this age of gene editing,
which ushers in the writing as well as reading of the human genetic
code.111 Our genes interact internally and with our environment 112 in
ways that are beyond our current understanding, not least as to the
precise consequences of gene editing, and it is important that we do our
best to ensure that the phrase "precision medicine" turns out not to be a
misnomer. CRISPR-Cas9 may well be a more promising and precise
gene editing tool than any we have had before but the ongoing effects of
its application are far from clear, both scientifically and in terms of
wider societal outcomes. Negative consequences-not least in terms of
potentially patenting as a chimera a significantly human organism-
and erosion of personhood, must be considered even, or especially, as the
forward thrusts of scientific discovery and technological application
promise exciting cures. History does indeed seem to repeat itself and
elimination of illness and deemed defect has, as we have seen, been a
temptation badly mishandled in the past, and not so distant past. 113
Treatments for rare diseases, which have not tended to attract
significant capital, could well be assisted by modification of the human
genome, but it is not clear that the benefits of gene-editing will be
shared with uncommonly afflicted individuals. Nor are those who suffer
from more common illnesses guaranteed affordable medicine, with
examples of price-gouging in the pharmaceutical sector, 114 and patient
protections in the Affordable Care Act under threat. 115 Yet there are
suggesting to his young companion, Glaucon, that they look for justice in a city rather
than in an individual man. After attributing the origin of society to the individual not
being self-sufficient and having many needs which he cannot supply himself, they go on to
describe the development of the city. Socrates first describes the "healthy state," but
Glaucon asks him to describe "a city of pigs," as he says that he finds little difference
between the two. Socrates then goes on to describe the luxurious city, which he calls "a
fevered state." This, he feels, requires a "guardian class" to defend and attack on its
account. See PLATO, supra note 55.
111. See generally SIDDHARTHA MUKHERJEE, THE GENE: AN INTIMATE HISTORY (2017)
(tracing the history and development of the human understand of the gene).
112. See Weinhold, supra note 78, for a discussion of epigenetics.
113. See supra pages 711-712.
114. Note, for example, the 5000% increase in a drug price-the drug still costs 2,500%
more than before the arbitrary price rise. Andrew Pollack, Drug Goes From $13.50 a
Tablet to $750, Overnight, N.Y. TIMES (Sept. 20, 2015), https://www.nytimes.com/
2015/09/2 1/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html;
Heather Long, Here's What Happened to AIDS Drug that Spiked 5,000%, CNN MONEY
(Aug. 25, 2016, 12:10 PM), http://money.cnn.com/2016/08/25/news/economy/daraprim-aids-
drug-high-price/index.html.
115. See Act of Dec. 22, 2017, Pub. L. No. 115-97, § 11081, 131 Stat. 2054, 2092; see also
Exec. Order No. 13,813, 82 Fed. Reg. 48,385 (Oct. 12, 2017).
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countervailing influences, as in the Myriad Genetics case, 116 which
called a halt to the systematic patenting of unmodified human genes.
Prior to such patent claims, these might well have been viewed as part
of the common heritage of mankind. Orthodox patent law had
traditionally not allowed patents on products of nature, which is how
merely isolated genes might well be described. It took the Supreme
Court of the United States ultimately to rule out such patents 117 and, in
a series of cases, 118 to rein in the United States Court of Appeals for the
Federal Circuit, which had previously 19 displayed a rather instinctively
pro-patent approach across a range of issues, 120 perhaps for a time
losing sight of the fact that over-patenting things and creatures that are
not, in traditional patent law terms, truly inventive or patentable, can
have a chilling effect on innovation.
The advent of embryonic human-nonhuman chimeras, accompanied
by the marriage of CRISPR-Cas9 to stem cell technology, threatens to
challenge and even redefine what it means to be human. It would be
lamentable if, despite the prohibition in Section 33 (a) of the America
Invents Act, a modified human being, in the garb of a chimera, were to
lurch through the system and be patented. And will such human-
nonhuman animal chimeras be regarded as persons for constitutional
purposes? Be prepared for gradual, almost casual, abrasion of
personhood.
Thomas Larsson, in his book, The Race to the Top: The Real Story of
Globalization, states that globalization "is the process of world
shrinkage, of distances getting shorter, things moving closer. It pertains
to the increasing ease with which somebody on one side of the world can
interact, to mutual benefit, with somebody on the other side of the
world." 121 The word "mutual" in that quote gives pause for doubt in
terms of what the author alleges is the "real story" of globalization. I
116. See Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576,
590 (2013) (considering the "delicate balance between creating 'incentives that lead to
creation, invention, and discovery' and 'imped[ing] the flow of information that might
permit, indeed spur, invention."').
117. See id. Note also that attempts by Myriad Genetics to obtain injunctive relief
against a variety of organizations, (post-Myriad Genetics in the Supreme Court), have
failed, confirming the futility of Justice Thomas's attempt to create a meaningful legal
distinction between copy DNA (cDNA) and DNA.
118. See, e.g., Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 87-91
(2012).
119. Compare, more recently, In Re Roslin Inst. (Edinburgh), 750 F.3d 1333 (Fed. Cir.
2014).
120. See Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d
1303, 1324-33 (Fed. Cir. 2012).
121. TOmAS LARSSON, THE RACE TO THE TOP: THE REAL STORY OF GLOBALIZATION 9
(2001).
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suppose it depends on how one defines mutuality.
In the sense of closeness with those in other parts of the world, the
ultimate globalization could be said to come with the knowledge and
digitization of how similar human genomes are to one another and with
the observation that the percentage differences between nonhuman
animal genomes and human genomes are surprisingly slight: as, to
some extent, are those between plant and human genomes. Yet that
perspective, based on an even approximate percentage calculation of
genes, is in danger of leaving out the human element-the humanness
of us all. Whilst it is important that we do not stifle or unnecessarily
impede promising biomedical development, we should proceed
cautiously to avoid undermining, incrementally and ironically, the very
humanness that we seek to protect in our search for restorative organs
and other improvements. Inquire, potentially, of the sources of the
organs and spare parts that scientists are working so hard to modify in
the human-nonhuman chimeras. You, or the patent office, determine
the essential proportions.
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